Our ADCs target difficult-to-treat cancers, including those that are resistant or refractory to current therapies.
Through our highly experienced ADC Development Team, we are building a pipeline of best in class ADCs with superior therapeutic index (TI).
Our approach is to develop the best ADCs for each tumour or tumour sub-type through careful selection of the right combinations of payload, linker and conjugation chemistry.
Iksuda has built a portfolio of ADC assets including;
- PermaLink® – our proprietary conjugation chemistry for improved ADC stability
- Novel payloads with a variety of mechanisms for improved tumour killing, including pro-drug approaches for added safety
- Novel antibodies towards targeted well-selected antigens associated primarily with solid tumours
In addition to Iksuda’s proprietary pipeline of best-in-class ADCs, we seek strategic collaborations and licensing opportunities for ADCs which also meet our criteria.
We are focused on providing more effective treatments for patients who have few options, and our pipeline targets tumours including diffuse B-cell lymphomas, lung cancer, gynaecological tumours such as those of the ovary & cervix, pancreatic, triple-negative breast cancer and colorectal cancer.
Our first wave ADC programmes target antigens with proven premise in ADC formats and include novel DNA damaging payloads with tumour-activating pro-drug mechanisms.
We are working with leading research institutions in the US and Europe to develop exciting new therapies for the future. We are flexible in our approach to collaboration and welcome discussions with research groups who have novel ADC-relevant programmes.
We have developed a series of high-value ADC assets, which are available for collaborative research and license.